Evidence map›Paper›PMID 39317451›Full record

ArticleThorax2024

Implications of the 2022 lung function update and GLI global reference equations among patients with interstitial lung disease.

Andrew Li, Alan Teoh, Lauren Troy, Ian Glaspole, Margaret L Wilsher, Sally de Boer, Jeremy Wrobel, Yuben P Moodley, Francis Thien, Henry Gallagher and 19 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Thorax, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Observational
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Andrew LiDepartment of Medicine, Respiratory Service, Woodlands Health, Singapore.ORCID 0000-0003-1516-3454
Alan TeohDepartment of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
Lauren TroyDepartment of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
Ian GlaspoleAlfred Hospital, Melbourne, Victoria, Australia.
Margaret L WilsherRespiratory Services, Auckland District Health Board, Auckland, New Zealand.
Sally de BoerGreen Lane Respiratory Services, Auckland City Hospital, Auckland, New Zealand.
Jeremy WrobelDepartment of Respiratory Medicine, Fiona Stanley Hospital, Murdoch, Western Australia, Australia.
Yuben P MoodleyDepartment of Respiratory Medicine, Fiona Stanley Hospital, Murdoch, Western Australia, Australia.
Francis ThienDepartment of Respiratory Medicine, Eastern Health and Monash University, Box Hill, Victoria, Australia.
Henry GallagherWaikato Hospital, Hamilton, New Zealand.
Michelle GalbraithWaikato Hospital, Hamilton, New Zealand.
Daniel C ChambersQueensland Lung Transplant Service, The Prince Charles Hospital, Chermside, Queensland, Australia.
John MackintoshDepartment of Thoracic Medicine, The Prince Charles Hospital, Chermside, Queensland, Australia.ORCID 0000-0002-5254-4144
Nicole GohRespiratory and Sleep Medicine Department, Austin Health, Heidelberg, Victoria, Australia.
Yet Hong KhorRespiratory and Sleep Medicine, Austin Hospital, Heidelberg, Victoria, Australia.ORCID 0000-0002-5434-9342
Adrienne EdwardsRespiratory Department, Christchurch Hospital, Christchurch, Canterbury, New Zealand.
Karen RoyalsDepartment for Health and Ageing, Respiratory Nursing Service, Adelaide, South Australia, Australia.
Christopher GraingeUniversity of Newcastle, Callaghan, New South Wales, Australia.
Benjamin KwanDepartment of Respiratory and Sleep Medicine, Sutherland Hospital, Caringbah, New South Wales, Australia.
Gregory J KeirUniversity of Queensland, St Lucia, Queensland, Australia.
Chong OngDepartment of Respiratory and Sleep Medicine, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia.
Paul N ReynoldsDepartment of Respiratory Medicine, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Elizabeth VeitchDepartment of Thoracic Medicine, Concord Hospital, Concord, New South Wales, Australia.
Gin Tsen ChaiDepartment of Respiratory and Critical Care Medicine, Tan Tock Seng Hospital, Singapore.ORCID 0000-0003-0758-6895
Ziqin NgDepartment of Respiratory and Critical Care Medicine, Tan Tock Seng Hospital, Singapore.
Geak Poh TanDepartment of Respiratory and Critical Care Medicine, Tan Tock Seng Hospital, Singapore.
Dan JacksonSydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
Tamera CorteDepartment of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
Helen JoDepartment of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia Helen.Jo@health.nsw.gov.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLung function testing remains a cornerstone in the assessment and management of interstitial lung disease (ILD) patients. The clinical implications of the Global Lung function Initiative (GLI) reference equations and the updated interpretation strategies remain uncertain.

methodsAdult patients with ILD with baseline forced vital capacity (FVC) were included from the Australasian ILD registry and the National Healthcare Group ILD registry, Singapore.The European Coal and Steel Community and Miller reference equations were compared with the GLI reference equations to assess (a) differences in lung function percent predicted values; (b) ILD risk prediction models and (c) eligibility for ILD clinical trial enrolment.

resultsAmong 2219 patients with ILD, 1712 (77.2%) were white individuals. Idiopathic pulmonary fibrosis (IPF), connective tissue disease-associated ILD and unclassifiable ILD predominated.Median FVC was 2.60 (2.01-3.36) L, forced expiratory volume in 1 s was 2.09 (1.67-2.66) L and diffusing capacity of the lungs for carbon monoxide (DLCO) was 13.60 (10.16-17.60) mL/min/mm Hg. When applying the GLI reference equations, the mean FVC percentage predicted was 8.8% lower (87.7% vs 78.9%, p<0.01) while the mean DLCO percentage predicted was 4.9% higher (58.5% vs 63.4%, p<0.01). There was a decrease in 19 IPF and 119 non-IPF patients who qualified for the nintedanib clinical trials when the GLI reference equations were applied. Risk prediction models performed similarly in predicting mortality using both reference equations.

conclusionApplying the GLI reference equations in patients with ILD leads to higher DLCO percentage predicted values and smaller lung volume percentage predicted values. While applying the GLI reference equations did not impact on prognostication, fewer patients met the clinical trial criteria for antifibrotic agents.

Indexed as

Lung Diseases, InterstitialAgedFemaleForced Expiratory VolumeHumansMaleMiddle AgedReference ValuesRegistriesRespiratory Function TestsVital CapacityConnective tissue disease associated lung diseaseIdiopathic pulmonary fibrosisInterstitial FibrosisPulmonary vasculitisRare lung diseases

Identifiers

PMID39317451
PMCPMC11503192

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.